

EXECUTIVE DIRECTORS



Richard Armitage Chief Financial Officer



Jakob Sigurdsson Chief Executive Officer



Martin Court
Chief Commercial Officer



PROACTIVELY MANAGING COVID CHALLENGES

OUR PEOPLE

- Safety, health & well-being our highest priority
- >70% of global employees homeworking
- Multiple global community programmes supported, including PPE donations, mask manufacture, 3D printed applications

OUR CUSTOMERS

- > 99%+ on time in full (OTIF) through FY 2020
- Strong inventories (c16 weeks sales stock)
- Supplying life-sustaining devices eg Ventilator equipment for multiple customers

OUR FINANCIAL POSITION

- Resilient despite 23% decline in H2 sales
- Cash generative with conservation measures
 - £73.1m cash, reinstated dividends
 - UK debottlenecking paused
 - Cost savings & headcount reduction
 - £40m facilities (RCF undrawn)



STRENGTHENING OUR BUSINESS - UNDERPINNING PROFITABILITY

GROWING OUR PIPELINE:


+9% Mature Annualised Revenue

• ROBUST SUPPLY CHAIN:

99%+ on time in full (OTIF)

CUSTOMER EXPERIENCE (CX)

Combined sales & technical service



SALES FROM NEW PRODUCTS IMPROVEMENT:

5% vs 4% in FY 2019

MEGA-PROGRAMME MILESTONES:

c80% of milestones hit in FY 2020



ENERGY

- COST MANAGEMENT:
 - c100 roles removed, primarily voluntary
 Underpin margin & support l/term operating leverage
- INTEGRATED BUSINESS PLANNING:
 Enhancing supply & demand balance



>85% renewable electricity



MANUFACTURING & ENGINEERING

CHINA

Growth investment







ELECTRONICS

AEROSPACE EL

HIGHLIGHTS

FY IMPACTED BY SIGNIFICANT COVID HEADWINDS IN H2

- FY sales volume down 7% & revenue down 10%, impacted by end-market weakness in H2
- H2 revenue down 23%, subsequent signs of having bottomed out in Auto, Electronics and Medical, with incremental improvement
- Medical revenue down 14%, with US remaining weak and Asia improving
- Underlying PBT down 29% at £75.5m; continuing margin impact from under absorption of fixed costs
- Reported PBT of £63.5m, reflecting £12m of exceptional items in FY 2020 driven by cost actions; anticipated annualised savings of c£10m

LONG TERM GROWTH PIPELINE REMAINS STRONG; LITTLE EVIDENCE OF SLOWDOWN

- Meaningful revenue of £1m+ delivered for Aerospace Loaded Brackets programme
- PEEK indicated as 'material of choice' by TechnipFMC for Magma oil & gas qualification programme
- PEEK Knee clinical trial underway, with additional trial sites being prepared
- New E-mobility growth programme gaining traction

INVESTMENTS UNDERPIN FUTURE GROWTH OPPORTUNITIES

- New PEEK manufacturing facility in China progressing, to stimulate growth
- Further progress to enhance our Additive Manufacturing (3D printing) capability

RESILIENT FINANCIAL POSITION WITH NET CASH; COST ACTIONS IMPLEMENTED

- FY cash £73.1m*; operating cash conversion of 101%¹
- Committed and undrawn RCF of £20m, with £20m accordion
- UK debottlenecking programme paused pending demand improvement
- Strong inventory position (FY 2020: £98.5m) to manage Brexit transition
- Reinstatement of dividends, with proposed final dividend of 46.14p/share





COVID IMPACT IN H2 2020

- FY 2020 sales volume down 7% to 3,492 tonnes (H2 2020 volume & revenue down 19% & 23%)
- Pronounced impact in Aerospace, Energy & Auto; Medical impacted as procedures deferred
- Margin 650bps lower driven by under-absorbed fixed costs
- Total overheads (excluding exceptional items) down 6%; reduced marketing, travel and discretionary spend

Year ended 30 September


				Change (constant
	FY 2020	FY 2019	Change	currency) ¹
	£m	£m	%	%
Revenue	266.0	294.0	-10%	-10%
Losses on foreign currency net hedging*	(1.5)	(5.9)	-75%	
Gross profit	142.4	176.3	-19%	-23%
Gross margin %	53.5%	60.0%	-650bps	
Overheads**	(66.9)	(70.8)	-6%	-4%
Exceptionals	(12.0)	(1.5)	700%	700%
Interest	0.0	0.7	-100%	-100%
Underlying profit before tax ¹	75.5	106.2	-29%	-34%
Profit before tax	63.5	104.7	-39%	-46%
Adjusted earnings per share (pence)	75.3	108.9	-31%	NA
Earnings per share (pence)	62.6	107.2	-42%	NA
Dividend per share	46.14p	59.56p	-23%	NA

^{*} Losses on foreign currency contracts, when net hedging is applied on cash flow hedges, are disclosed separately within gross margin on adoption of IFRS 9.

^{**} Excluding exceptional items of £12.0m (FY19: £1.5m)

FY 2020 vs FY 2019

PBT bridge...



PBT IMPACTED BY UNDER-ABSORBED FIXED COSTS

- Under-recovered overhead from lower production volume vs sales volume
- Growth investment up £2m
- Exceptional items driven primarily by cost actions & China M&A costs

ASP & MARGIN

Robust ASP, Margin impacted



£/kg Average selling price (ASP)



FY 2020 ASP £76.1/kg (down 3%)


- Underlying pricing broadly stable
- Softer mix weighted towards H2

FY 2020 GM 53.5% (down 650bps)

 Margin materially impacted by under-absorbed fixed costs and lower production

MARGIN HISTORY & OUTLOOK

Gross margin history from FY 2016



UNDER-ABSORBED FIXED COSTS REMAIN KEY IMPACT ON MARGIN

- Significant under-absorption impact on margin in FY 2020, driven by lower production volumes
- Investment in parts since 2015
- Currency benefit offset by IFRS9 (200 bps impact from FY 2019)
- Margin recovery opportunity when end-market demand improves

CURRENCY

FY21 headwind...

				_0.5		-	
vind	Reported	Exc deals	Currency Spot Impact	Constant currency 1	As reported	Exc Deals	Constant currency 1
	£m	£m	£m	£m	£m	£m	£m
Revenue	266.0	266.0	(1.7)	264.3	294.0	294.0	-10%
Loss on foreign currency net hedging	(1.5)	-	-	-	(5.9)	-	1070
Gross profit	142.4	143.9	(4.1)	139.8	176.3	182.2	-23%
Gross margin %	53.5%	54.1%	-	52.9%	60.0%	62.0%	
Profit before tax	63.5	65.0	(5.6)	59.4	104.7	110.6	-46%
Exchange rates	FY 2019 ³	FY 2019 ²	FY 2020 ³	FY 2020 ²	FY 2021 ³	FY 2021 ²	Exchange rate sensitivity 4

2020

2019

Change

Exchange rates	FY 2019 ³	FY 2019 ²	FY 2020 ³	FY 2020 ²	FY 2021 ³	FY 2021 ²	rate sensitivity 4
\$/£	1.28	1.35	1.27	1.26	1.30	1.28	£4.6m
_€/£	1.13	1.11	1.13	1.11	1.10	1.12	£4.0m

- FY 2020 currency tailwind £10m at PBT
- FY 2021 currency headwind c£2m at PBT; >75% hedging in place

¹ Alternative performance measures are defined in the Appendix on slide 40

² Effective rates (includes the impact of hedging)


³ Weighted average spot exchange rates (before the impact of hedging)

⁴ Management estimate of impact on 2020 full year forecast PBT from a 5% movement in weighted average spot exchange rates (before the impact of hedging)

INVENTORY & BREXIT

Brexit ready for customers...







- FY 2020 inventory £98.5m (FY 2019: £92.2m)
 - Raw material inventory build through FY 2020; c16 weeks sales inventory in place
 - Sales inventory unwind post-Brexit from 2021
- Brexit ready for customers
 - Warehousing in Germany fully operational; servicing European customers
 - Optionality to relocate REACH registrations (UK or EU entities)
 - Potential for tariff mitigation under EU law (in event of No Deal)

CHINA INVESTMENT

Underpin future growth...





- Construction progressing for China manufacturing subsidiary
- Key milestones delivered with c300 contractors on site
- On track for commissioning in 2022

CAPITAL INVESTMENT

Efficient use of cash...



- Debottlenecking paused, pending clearer signs of sustained demand
- FY 2021 total capex >£40m

CASH

Strong cash generation

	FY2020	FY2019
	£m	£m
Operating profit before tax & ex	76.0	105.6
Depreciation & amortisation	20.9	17.5
EBITDA	96.9	123.1
Change in working capital	4.8	(32.9)
Capital expenditure	(24.9)	(22.7)
Operating cash flow	76.8	67.5
Operating cash conversion	101%	64%
Interest received	0.3	0.7
Interest paid	(0.3)	-
Tax	(17.2)	(10.9)
Exceptional costs	(12.0)	(1.5)
Other	(3.1)	1.6
Free cash flow	44.5	57.4
Acquisitions	(4.9)	(11.8)
Dividends	(39.9)	(122.4)
Other	1.5	77.2
Net cash flow	1.2	0.4
Exchange differences	(0.6)	0.9
Net cash at 1st October	72.5	71.2
Net cash at 30th September	73.1	72.5

SUPPORTING GROWTH & DIVIDEND RETURNS

- Operating cash conversion 101%
- Prioritise growth investment
- Reinstated FY 2020 dividends (final dividend 46.14p)
- Strong mid-term dividend return opportunities

STRONG BALANCE SHEET & FINANCIAL RESILIENCE

- £20m RCF (undrawn), £20m accordion and options for additional debt facilities
- Stress-test scenarios completed for potential downside scenarios

PERFORMANCE UPDATE

Everyday, millions of people rely on products and applications containing our sustainable highperformance PEEK and PAEK polymer solutions

MEDICAL

~ 13 million implanted devices

worldwide use Invibio PEEK-OPTIMA™ polymers

INDUSTRIAL& **MANUFACTURING** & ENGINEERING

100⁺ million machines

operating using Victrex solutions



20,000⁺ aircraft

Have Victrex solutions onboard



4⁺ billion mobile devices

use APTIV™ Acoustic Film

ENERGY

75⁺ million VICTREX[™] PEEK seals

in use today

AUTOMOTIVE

500⁺ million gears in automotive applications made with VICTREX™ PEEK

INDUSTRIAL UPDATE



AUTOMOTIVE: INCREMENTAL IMPROVEMENT FROM Q4 ONWARDS

- FY 2020 Automotive -8%; good H1, COVID impact in H2, -40% at trough levels
- New E-mobility growth programme



AEROSPACE: STRONG PEEK PROPOSITION DESPITE CHALLENGING MARKET

- FY 2020 Aerospace –26%, COVID impact driving H2 volume –49%
- Meaningful revenue of £1m+ for Aerospace Loaded Brackets
- Airbus 'Clean Sky 2' programme progressing with prototype revenue



ENERGY & OTHER INDUSTRIAL: TOUGH ENERGY, MAGMA OPPORTUNITY

- H1 2020 Energy & Other Industrial down 8% (Oil & Gas down 25%)
- PEEK noted as "preferred material" by TechnipFMC for Magma opportunity



ELECTRONICS: STABLE PERFORMANCE

- FY 2020 Electronics down 6%; new Semicon opportunities & Home Appliances
- Launch of new grade DBX film

VALUE ADDED RESELLERS (VAR)

FY 2020 volumes -6%; solid growth until Q4 with subdued markets (-14% in H2)

AEROSPACE UPDATE

POLYMER & PARTS JOURNEY

Meaningful revenue for Aerospace Loaded Brackets, despite short term challenges

Loaded **MONOMER POLYMER FORMS PARTS** Brackets...

> 2014 Hybrid overmoulding process

2017 AETM250 composite tape

2019 TxV Aero Composites first parts produced

2020 Commercial orders Meaningful revenue >£1m

Mid-term Commercialise existing pipeline Larger parts Structural composites

AEROSPACE UPDATE

eVTOL – URBAN AIR MOBILITY

eVTOL...

Loaded brackets

Insulation applications & interior parts



Structural parts

EMERGING MARKET REQUIRING PEEK/PAEK COMPOSITE SOLUTIONS

- Good medium/long term opportunities, industry forecasts \$1.5 trillion market by 2040 (JP Morgan)
- Multiple engagements with OEMs and Tier players

AUTOMOTIVE UPDATE



~8g

c100g potential

E-mobility...

ICE



Mild-HEV



Full-HEV



BEV





- CHASSIS
- ENGINE
- FUEL FILTER
- TRANSMISSION
- GEARS





- BRAKES
- CHASSIS
- ENGINE
- FUEL FILTER
- TRANSMISSION
- GEARS



Hybrid Venicles

- BRAKES
- CHASSIS
- ENGINE
- GEARS
- TRANSMISSION
- E-MOTOR
- POWER ELECTRONICS
- BATTERY
 COMPONENTS &
 THERMAL
 MANAGEMENT



- BRAKES
- CHASSIS
- GEARS
- E-MOTOR
- E-AXLE
- POWER ELECTRONICS
- BATTERY COMPONENTS & THERMAL MANAGEMENT

Internal Combustion Engine

E-MOBILITY


Higher voltages = higher performance requirements...

ENGINE & E-MOTOR

- Cost-effective NVH
- Higher voltages
- Reliability (up to 30,000 RPM)
- Weight & inertia benefits
- Component simplification
- Longer vehicle lifetimes

POWER ELECTRONICS

- Improved efficiency, reduced losses
- Faster Switching (SiC, GaN)
- Heat transfer, enhanced cooling



THERMALMANAGEMENT

Cost-effective NVH

BATTERY

Structural integrity

Reliability & safety

Energy density

Cost of total system & per kWh

- Improved energy efficiency
- eMotor and battery temperatures

Mechanical strength

Current status... OEM Development (EU) Auto OEM (Asia) Tier/Auto OEM (Asia) Auto OEM (Asia)



2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029

DEVELOPMENT & VALIDATION PHASE

COMMERCIALISATION & EXPANSION

MULTIPLE GLOBAL DEVELOPMENT PROGRAMMES IN PROGRESS

- Focused on higher performance, higher voltage requirements (800V +)
- Strong fit for PEEK across e-motor, insulative & thermal management applications
- Short-mid term opportunity to commercialise existing development programmes



MEDICAL UPDATE



FY 2020 MEDICAL -14%

INCREMENTAL IMPROVEMENT SINCE SUMMER 2020

- FY 2020 Medical revenue -14% at £49.7m (FY 2019: £57.7m)
- US Spine remains subdued, incremental improvement in Asia
- Record year for HA-Enhanced, with £2m revenue and record approvals, including EU and South Korea
- Continuing development of 3D Porous PEEK FY22 focus
- Growth in non-Spine including CMF, Ventilators & related equipment





TRAUMA

GROWING DEMAND, DOUBLE-DIGIT GROWTH

- Multiple Trauma plate launches in FY 2021
- US developments progressing



DENTAL

ADOPTION CHALLENGES DESPITE CLINICAL PROPOSITION

- Continuation of clinical evidence build and Key Opinion Leader engagement
- Adoption contingent on supply chain partners, appropriate resourcing



KNEE

CLINICAL TRIAL RESTARTED

Italy trial restarted post-COVID impact; expanded into other sites (India)

MEDICAL STRATEGIC PILLARS

SPINE

Secure near-term meaningful revenues from PEEK-OPTIMA HA-Enhanced (FY19), Spinal Rods and porous PEEK (mid-term)



3D printed Porous PEEK cages
- FY22 opportunity

NON-SPINE

Grow non-Spine revenues (ex-Arthroscopy) to doubledigits mid-term



Further grow CMF, Cardio & other revenues

MEGA-PROGRAMMES

Deliver meaningful revenues from megaprogrammes in Horizon 2 (2-5 years)






Focus on near/mid-term Trauma & Knee revenues





MEGA-PROGRAMMES

Strong growth pipeline...



Size of bubble = potential annual revenue in peak year: <£20m £20-50m >£50m (all bubbles are indicative only) Position and colour of bubble = time to meaningful revenue: Horizon 1 (0-2 years) Horizon 2 (2-5 years) Horizon 3 (5 years +)

PIPELINE MILESTONES

PROGRAMME	REVENUE STATUS	FY 2020 MILESTONES	FY 2021 FOCUS				
MAGMA	Meaningful (£1m-£2m)	 "Material of choice" for Brazil qualification (Technip FMC) North Sea & Gulf deployments 	 Support manufacture of TechnipFMC qualification pipe Build revenue from incremental projects 				
HA-ENHANCED	Meaningful (£1m-£2m)	 Doubled revenue to £2m Record approvals inc EU/S Korea 	 Grow revenues >£2m Europe approvals and commercialisation 				
AERO BRACKETS	Meaningful (£1m-£2m)	Meaningful revenue deliveredCommercial orders (seat pans, brackets)	 Build repeat orders, increase revenue beyond £1m Further develop eVTOL opportunities 				
GEARS	< £1m	 US and China OEM qualifications Expansion: 25 development programmes Manufacturing ready 	 Achieve meaningful revenue of £1m-£2m Commercialise development agreements (opportunity for 5 supply programmes – existing & new) 				
DENTAL	< £1m	 Further positive mid-term clinical data (Malo) 	 Exploring adoption through OEM partners Further build clinical evidence including 5+ years data 				
TRAUMA	< £1m	Progressing OEM collaborationsManufacturing ready	Multiple plate launchesFirst OEM deployment				
AERO STRUCTURES	< £1m	 AE250 composites in demonstrator OEM collaboration for Clean Sky 2 programme 	 Progress with certification programmes Achieve meaningful revenue (prototype revenue) 				
KNEE	n/a	Clinical trial restarted (Italy)	 Progress and expand additional trial sites (EU, Asia) Capitalise on existing OEM interest 				
E-MOBILITY	n/a	 Multiple global development programmes (c10 opportunities) PEEK ability to meet higher voltage 	 Validation and early commercial revenues Commitments to OEM and tier programmes Progress to support production scale up in FY 2022 				



SUSTAINABILITY & ESG

A strong proposition so far...



SUSTAINABLE SOLUTIONS

Develop and deliver sustainable polymer solutions that provide clear social and environmental benefits to society















Sustainable products supporting CO2 reduction trends & providing environmental & social benefits



RESOURCE EFFICIENCY

Maximise resource efficiency across the value chain





Recyclability & circular economy



SOCIAL RESPONSIBILITY

Inspire the next generation by supporting science, technology, engineering and maths education ('STEM')





FTSE Russell
Green Revenues Index

A NEW SUSTAINABILITY VISION

ACHIEVE CARBON NET ZERO:

- INCREASE THE USE OF OUR SUSTAINABLE & RECYCLABLE PRODUCTS WHICH SUPPORT CO2 REMOVAL
 - MINIMISE RESOURCES (CARBON, WASTE AND WATER) USED IN OUR OPERATIONS

SUSTAINABILITY PILLARS

2030 GOALS

MILESTONE TARGETS










SUSTAINABLE SOLUTIONS AND RESOURCE EFFICIENCY



ACHIEVE NET ZERO CARBON EMISSIONS

by 2030 in our own operations ¹

INCREASE RECYCLING RATES of PEEK/PAEK in the supply chain

INCREASE REVENUE from our sustainable products with positive environmental & social benefits⁴ (currently c40%)

SUSTAINED REDUCTION IN RESOURCES (carbon, waste and water) per tonne by 2030 **VICTREX USING 100% RENEWABLE ELECTRICITY WITHIN 3 YEARS 2**

DOUBLE RECYCLING RATES in the supply chain by 2025

EXCEED 50% OF GROUP REVENUE from sustainable products with environmental & social benefits by 2025

COMMITMENT TO A SCIENCE BASED **EMISSIONS TARGET 3 BY 2022**



SUSTAINABLE DEVELOPMENT GOALS

Z









SOCIAL RESPONSIBILITY



DELIVER A ZERO ACCIDENT AND INCIDENT CULTURE

GROW global STEM programme

INCREASE COMMUNITY ACTIVITY across our global locations

FOCUS on enhancing gender equality/Diversity and Inclusion IMPROVED SAFETY METRICS, BASED ON **OSHA STANDARD**


STEM AMBASSADORS in every region

COMMIT >500 EMPLOYEE HOURS to global community activity annually

EMBED INCLUSION AND DIVERSITY across global employee base

GROUP OUTLOOK

FY 2021*





Indicative outlook for our markets for FY 2021



SUMMARY

FY21 OUTLOOK: "FY progress contingent on improving macro & end-markets in H2 2021"

- Incremental demand improvement since end of FY 2020
- Potential for uncertain order patterns in H1
- Continued under-absorption (inventory unwind post Brexit)
- Cost actions to benefit long-term operating leverage

MID & LONG-TERM OUTLOOK:


- Strong financial position & improving cash generation
- Strong ESG agenda: sustainable products delivering environmental & societal benefit
- Strong growth pipeline with improving mega-programme milestones
 - Continued progress and little evidence of mega-programme slowdown through COVID
 - Adding to growth pipeline




GROUP END MARKETS

FY 2020: 3,492 tonnes

FY 2019: 3,751 tonnes




Asia



^{*} Medical volume reflects both non-implantable and implantable volumes # Includes Manufacturing & Engineering volumes

Volume by Industry




MEDICAL: KEY MARKETS


FY 2020: £49.7m

FY 2019: £57.7m

Revenue by Region



Revenue by Market



BUSINESS UNIT INCOME STATEMENTS

	2020				2019			
	Reported	Exc deals	Currency Spot Impact	Constant currency 1	As reported	Exc Deals	Constant currency 1	
	£m	£m	£m	£m	£m	£m	£m	
Industrial								
Revenue	216.3	216.3	(1.3)	214.9	236.3	236.3	-9%	
Loss on foreign currency net hedging	(1.0)	-	-	-	(3.9)	-		
Gross profit *	99.3	100.3	(3.6)	96.7	128.2	132.1	-2 <mark>7%</mark>	
Gross margin %	45.9%			45.0%	54.3%	55.9%		
_								
Medical								
Revenue	49.7	49.7	(0.4)	49.3	57.7	57.7	-14%	
Loss on foreign currency net hedging	(0.6)				(2.0)	-		
Gross profit *	43.0	43.6	(0.5)	42.5	48.1	50.1	-15%	
Gross margin %	86.5%			86.2%	83.4%	86.8%	¥ ,	

¹ Alternative performance measures are defined in the Appendix on slide 40

BALANCE SHEET

	FY 2020	FY 2019	
	£m	£m	_
PPE and intangible assets	300.1	288.2	•
Investment in associated undertakings	12.3	8.2	
Financial assets held at fair value through profit and loss*	8.0	8.0	
Inventories	98.5	92.2	
Cash**	73.1	72.8	
Trade receivables and other assets	50.0	57.7	
Retirement benefit asset	7.5	9.1	
Trade payables and other liabilities	(68.5)	(74.6)	_
Equity shareholders' funds	481.0	461.6	

^{*} Financial assets held at fair value through profit and loss ("FVTPL") which represents the Group's minority investments ** Includes £5.6m of cash that sits in the joint venture in China and is effectively "restricted"

FUTURE USE OF CASH PRIORITIES

Investment for growth remains the priority

CAPEX

- Normalised capex c5-6% of sales
- Periodic investment in capacity & innovation

M&A / INVESTMENT

- Developing capability
- Further investments to support megaprogrammes & growth

REGULAR DIVIDENDS

- Average growth c6% over last 5 years
- Grow in line with EPS

SPECIAL DIVIDENDS

- Policy retained at c50% of net cash
 £85m threshold
- 50p/share minimum

DEFINITIONS

ALTERNATIVE PERFORMANCE MEASURES:

- 1) Constant currency metrics are reached by applying current year (FY 2020) weighted average spot rates to prior year (FY 2019) transactions. Gains and losses on foreign currency net hedging, are shown separately in the Income Statement and are excluded from the constant currency calculation;
- 2) Underlying PBT is profit before exceptional items and tax;
- 3) Operating cash conversion is operating profit before exceptional items adjusted for depreciation and amortisation, working capital and capital expenditure / operating profit before exceptional items;
- 4) Available cash is cash and cash equivalents plus other financial assets (cash invested in term deposits greater than three months in duration) less cash held in the Group's PVYX subsidiary;
- 5) Return on Capital Employed (ROCE) is profit after tax / total equity attributable to shareholders at the year end;
- 6) Operating overheads is made up of sales, marketing and administrative expenses before exceptional items; and
- 7) Underlying EPS is earnings per share based on profit after tax but before exceptional items divided by the weighted average number of shares in issue.

EXPERTS

First to commercialise PEEK, with unmatched knowledge and experience



INFORMATION & CONTACTS

Andrew Hanson

Director of IR & **Corporate Communications**

> +44 (0) 1253 898121 +44 (0) 7809 595831 ir@victrex.com www.victrexplc.com

DIFFERENTIATE THROUGH INNOVATION

TO CREATE NEW MARKETS











ENERGY



UNDERPIN: SAFETY, SUSTAINABILITY

- Health & safety
- Sustainable business with sustainable products



POLYMER MANUFACTURING

Delivering the key PEEK & PAEK materials with No.1 manufacturing capacity of 7,150 tonnes



POLYMER

Producing new grades including for Additive Manufacturing (3D Printing)



PARTS & COMPONENTS

Developing new applications for PEEK, PAEK and Thermoplastic Composites



INVESTMENT IN INNOVATION

GLOBAL CAPABILITY

800⁺

Employees

40+

Countries served by Victrex across our markets

c£2bn

Market Value

- FTSE 250 Company
- c£300m Revenue

PRODUCT FORMS

Manufacturing product forms: Pipes, Films, Fibres and Composite Tapes

c5-6% c£150m

of annual sales invested in R&D

Invested in manufacturing facilities in the last 5 years

NEW CAPABILITIES

- Partnerships
- Strategic Alliances
- Polymer Innovation Centre
- Acquisitions
- Composites Manufacturing
- Additive Manufacturing